EntryPoint Capital’s Bicycle Therapeutics BCYC Stock Holding History

EntryPoint Capital’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$330K	Buy	77,743 +13,837	+22%	+$63.4K	0.08%	505
2026 Q1	$297K	Buy	+63,906	New	+$365K	0.09%	474
2025 Q2	–	Sell	-28,857	Closed	-$245K	–	624
2025 Q1	$245K	Sell	28,857 -15,016	-34%	-$177K	0.11%	439
2024 Q4	$614K	Buy	+43,873	New	+$940K	0.26%	52
2024 Q1	–	Sell	-18,495	Closed	-$334K	–	1436
2023 Q4	$334K	Buy	+18,495	New	+$306K	0.32%	16

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSK plc London $602M AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

EntryPoint Capital's BCYC Position: Q2 2026 in Review

EntryPoint Capital increased its Bicycle Therapeutics (BCYC) stake by 22% in Q2 2026, buying an estimated $63.4K and bringing the position to 77,743 shares worth $330K. The position accounts for 0.08% of the portfolio, ranked #505.

EntryPoint Capital first reported a position in BCYC in Q4 2023 and has held it in 5 quarters since. The position peaked at $614K in Q4 2024. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

EntryPoint Capital held 77,743 shares of Bicycle Therapeutics worth $330K as of Q2 2026.
EntryPoint Capital bought 13,837 Bicycle Therapeutics shares in Q2 2026, an estimated $63.4K.
Bicycle Therapeutics made up 0.08% of EntryPoint Capital's portfolio in Q2 2026, its #505 holding.
EntryPoint Capital first reported a position in Bicycle Therapeutics in Q4 2023 and has held it in 5 quarters since.
EntryPoint Capital's Bicycle Therapeutics position peaked at $614K in Q4 2024.
104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.